All News

Watch Louise Gunter, from Texas Oncology, discuss IO/TKI-related side effects, during the CURE Educated Patient Kidney Cancer Summit.

An interview with Margaret Campbell, B.S.N, RN, the winner of the 2022 Extraordinary Healer® award.

Not only have Margaret Campbell's, own patients benefited from her dedication, but so many patients in the United States and around the world have access to better treatments due to her contributions.

Throughout my cancer experience, I’ve relied heavily on friends and family for support. But as they are moving on and starting families of their own, I realized how much time I’ve lost to cancer.

From an osteosarcoma survivor modeling inclusivity in the fashion world to rock guitarist Paul “Bonehead” Arthurs being diagnosed with cancer, here’s what’s happening in the cancer space this week.

Watch Dr. Jeff Yorio, from Texas Oncology, discuss treatment with the combination of immunotherapy and tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

After Enhertu showed promising clinical trial results, the Food and Drug Administration agreed to speed up the development and review of the drug for certain patients with unresectable or metastatic breast cancer.

Chemotherapy-induced peripheral neuropathy is a common side effect of patients undergoing cancer treatment, though many patients are not fully informed about the condition before their therapy starts.

Well-meaning comments can come off as bothersome — or even hurtful — to me as I navigate cancer.

For the first time in three years, CURE® welcomed 500 attendees in person and hundreds more virtually to honor the 2022 Extraordinary Healer® award recipient.

The first patient was dosed in the CLAUDIO-01 trial, analyzing SOTO102 in patients with certain types of gastric and pancreatic cancers.

From my “game-day uniform” to a playlist that made me feel ready to seize the day, here’s what helped me prepare for my days in cancer treatment.

Before being diagnosed with neuroendocrine cancer, I started to live a healthier life and took notice of some concerning symptoms.

Imfinzi alone is the standard of care in this patient population, however two combinations may have better outcomes.

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss communicating with a care team about treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

The majority of patients with relapsed/refractory large B-cell lymphoma were alive between four and five years after being treated with axi-cel.

The FDA granted a Fast Track designation to ofra-vec plus paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.

If there was a certain diet that could prevent my daughter from going through the perils of chemotherapy, she’d do it in a heartbeat. But science doesn’t back the sugar-feeds-cancer myth.

Alex Mallonee has found it inspiring to depict his mother’s journey with breast cancer through art, and hopes others affected by cancer will feel the same.

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss side effects and dose reductions after treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

The drug, known as BDTX-1535, is being investigated in patients with glioblastoma that harbors EGFR alterations and non-small cell lung cancer that harbors EGFR mutations of intrinsic or acquired resistance and disease that has failed standard treatment.

A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.

After my breast cancer metastasized to my lungs, I was put on a PARP inhibitor, which caused an unexpected side effect that, unfortunately, happens like clockwork.

Treatment with a combination of Ofev and chemotherapy was shown to have a survival benefit in a group of patients with bladder cancer.

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss the treatment of combining immunotherapy with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Thomas Hutson, Dr. Jose Karam, Dr, Naomi Haas, and Kiran Kehoe answer questions about frontline therapy during the CURE Educated Patient Kidney Cancer Summit.

Watch Dr. Naomi Haas, from Abramson Cancer Center, discuss adjuvant therapy options, during the CURE Educated Patient Kidney Cancer Summit.

Once a recommended dose of the drug is determined, the study investigators will review the efficacy and safety associated with this treatment across a variety of patients with bladder and liver cancer, as well other solid tumors.